| Name | Title | Contact Details |
|---|
Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have built our business model consistent with this belief, and through it, we are impacting people around the world with each passing year. Providing universal access to medicine is the core purpose of our model. To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.
Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate the Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 830 beds for medical, surgical, rehabilitation and hospice purposes. The Medical Center, Navicent Health – a nationally recognized tertiary teaching hospital and the primary teaching hospital for Mercer University School of Medicine - includes but is not limited to: •Peyton Anderson Cancer Center, Navicent Health, a provider of comprehensive cancer care. Our services cover the continuum of cancer care, from screening and diagnosis through treatment and into survivorship. •Emergency Center, Navicent Health provides access to our Level 1 Trauma Center and includes helipad capability. The Emergency Center, along with our three urgent care locations, treat over 120,000 visitors per year. •Family Birth Center, Navicent Health has spacious labor and delivery suites, focuses on providing a family-friendly and family-centered environment for expectant mothers and their babies, and specializes in care for difficult pregnancies. •Heart Center, Navicent Health provides a full range of services for the prevention, diagnosis and treatment of cardiovascular disease, including congestive heart failure. •Rehabilitation Hospital, Navicent Health is the oldest and most experienced medical rehabilitation provider in central Georgia providing comprehensive services to help patients achieve their highest level of mobility and independence. •Beverly Knight Olson Children`s Hospital, Navicent Health, the region`s only dedicated pediatric hospital Navicent Health is the region`s leading provider of a comprehensive continuum of services. Whatever your healthcare needs, Navicent Health is here to assist you and your loved ones.
Aegis Therapeutics LLC is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.